1st Quarter - Report

AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$138,170
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 19, 2016 $138,170 Replaced
1st Quarter - Amendment Jul 19, 2016 $191,860 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; and H.R. 2, the Medicare Access and CHIP Reauthorization of 2015.

LobbyistCovered position, as disclosed
JULIE A KHANI —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 6 (114th), H.R. 2 (114th)

Budget/Appropriations BUD

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and FY2017 Agriculture Appropriations.

LobbyistCovered position, as disclosed
JULIE A KHANI —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: H.R. 2 (114th), H.R. 6 (114th)

Medical/Disease Research/Clinical Labs MED

Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.

LobbyistCovered position, as disclosed
JULIE A KHANI —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Office of Management & Budget (OMB); SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 4909 (114th), H.R. 6 (114th), H.R. 2 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.